SCHEMBL23974180

SCHEMBL23974180

Fc1ccc(C2CCC(CCNC3CCCCC3)CC2)c(F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23974253 0.99 OPRL1 (1.00) OPRL1
SCHEMBL30127804 0.99 OPRL1 (1.00) OPRL1
SCHEMBL30127797 0.87 OPRL1 (1.00) OPRL1
SCHEMBL30127719 0.87 OPRL1 (1.00) OPRL1
SCHEMBL30127799 0.87 OPRL1 (0.77) OPRL1
SCHEMBL23974310 0.87 OPRL1 (1.00) OPRL1
SCHEMBL23974314 0.87 OPRL1 (1.00) OPRL1
SCHEMBL23974256 0.87 OPRL1 (1.00) OPRL1
SCHEMBL23974659 0.87 OPRL1 (1.00) OPRL1
SCHEMBL28561676 0.87 OPRL1 (1.00) OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144411-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS DART NEUROSCIENCE LLC 2023-05-11 US disclosed
US-20230144411-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS DART NEUROSCIENCE LLC 2023-05-11 US disclosed
EP-3759085-B1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS DART NEUROSCIENCE LLC (US) 2022-12-14 EP disclosed
US-11365191-B2 Substituted cyclohexyl compounds as NOP inhibiiors DART NEUROSCIENCE, LLC (US) 2022-06-21 US disclosed
US-20210340127-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS DART NEUROSCIENCE, LLC 2021-11-04 US disclosed
CN-112105605-A Substituted cyclohexyl compounds as NOP inhibitors 达特神经科学有限公司 2020-12-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340127-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS OPRL1, OPRK1, NOP56 OPRL1 1/4885
US-11365191-B2 Substituted cyclohexyl compounds as NOP inhibiiors OPRL1, OPRK1, GAP43 OPRL1 1/4885
US-20230144411-A1 SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS OPRL1, OPRK1, NOP56 OPRL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.